VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

VIVUS, Inc.

900 East Hamilton Avenue
Suite 550
Campbell, CA 95008
United States
650-934-5200
http://www.vivus.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Mr. John P. AmosCEO & Director745.17kN/A1967
Mr. Kenneth SuhPres537.12kN/A1976
Mr. Mark K. OkiSr. VP, CFO & Chief Accounting Officer575.34kN/A1969
Mr. John L. SlebirSr. VP of Bus. Devel., Gen. Counsel & Sec.748.66kN/A1965
Dr. Santosh T. VargheseChief Medical Officer581.8kN/A1970
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Corporate Governance

VIVUS, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.